Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluorouracil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | HBB | P68871 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | DPYD | Q12882 | 5/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.52 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorouracil SCHEMBL10017187 | 1.00 | — | — | |
| Fluorouracil SCHEMBL3646 | 1.00 | — | — | |
| Fluorouracil SCHEMBL31441196 | 0.97 | MAPT (0.95) | MAPTALDH1A1LMNACYP19A1TSHR | |
| Fluorouracil SCHEMBL21880166 | 0.97 | MAPT (0.95) | MAPTALDH1A1LMNACYP19A1TSHR | |
| Fluorouracil SCHEMBL30439198 | 0.97 | MAPT (0.95) | MAPTALDH1A1LMNACYP19A1TSHR | |
| Fluorouracil SCHEMBL11327829 | 0.97 | MAPT (0.95) | MAPTALDH1A1LMNACYP19A1TSHR | |
| Fluorouracil SCHEMBL7650203 | 0.97 | MAPT (0.95) | MAPTALDH1A1LMNACYP19A1TSHR | |
| Fluorouracil SCHEMBL21527805 | 0.97 | MAPT (0.95) | MAPTALDH1A1LMNACYP19A1TSHR | |
| Fluorouracil SCHEMBL15284932 | 0.97 | MAPT (0.95) | MAPTALDH1A1LMNACYP19A1TSHR | |
| Fluorouracil SCHEMBL28803776 | 0.97 | MAPT (0.95) | MAPTALDH1A1LMNACYP19A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 441 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240102993-A1 | Method of Selecting Chemotherapeutic Agents for an Isolated Organ or Regional Therapy | DELCATH SYSTEMS, INC. (US) | 2024-03-28 | — | — | US | claimed |
| CN-108265106-B | Method for predicting drug responsiveness in cancer patients | 亚拉勒提治疗欧洲私人有限公司 | 2022-11-29 | — | — | CN | claimed |
| CN-111012922-B | Medicine for targeted and controlled release treatment of colorectal cancer and preparation method thereof | 江南大学附属医院（无锡市第四人民医院） | 2022-11-08 | — | — | CN | claimed |
| CN-111671736-B | Metal organic framework-based drug carrier, preparation method thereof and application thereof in oral drug carrier | 辽宁大学 | 2022-06-14 | — | — | CN | claimed |
| CN-114555614-A | Anti-cancer compounds as non-PGP substrates | 深圳艾欣达伟医药科技有限公司 | 2022-05-27 | — | — | CN | claimed |
| CN-107135654-B | Macrocytic human anti-CD 46 antibodies and targeted cancer therapies | 加利福尼亚大学董事会 | 2021-10-29 | — | — | CN | claimed |
| CN-108778302-B | Method for preparing extract of showa herb, extract prepared thereby and use of the extract | 台湾生物技术开发中心 | 2021-10-15 | — | — | CN | claimed |
| WO-2021083310-A1 | ANTI-CANCER COMPOUNDS ACTING AS NON-PGP SUBSTRATE | 深圳艾欣达伟医药科技有限公司 | 2021-05-06 | — | — | WO | claimed |
| US-10369264-B2 | Apparatus for removing chemotherapy compounds from blood | DELCATH SYSTEMS, INC. (US) | 2019-08-06 | — | — | US | claimed |
| CN-107228895-B | A kind of detection method of the intracellular 5-flurocytosine and 5 FU 5 fluorouracil based on Capillary Electrophoresis | 东华大学 | 2019-06-04 | — | — | CN | claimed |
| WO-2012058269-A2 | METHODS OF TREATING CANCER AND OTHER DISEASES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-05-03 | — | — | WO | claimed |
| US-20120076777-A1 | ANTI-FIBROBLASTIC FLUOROCHEMICAL EMULSION THERAPIES | MTM RESEARCH LLC (US) | 2012-03-29 | — | — | US | claimed |
| WO-2012003457-A1 | ANTI-FIBROBLASTIC FLUOROCHEMICAL EMULSION THERAPIES | MTM RESEARCH LLC (US) | 2012-01-05 | — | — | WO | claimed |
| US-20090214669-A1 | Combination anticancer therapy and pharmaceutical compositions therefore | OM PHARMA (CH) | 2009-08-27 | — | — | US | claimed |
| US-20090208493-A1 | Compounds and methods for the selective inhibition of ABCB1, ABCC1 and ABCG2 transporters and the treatment of cancers, especially drug resistant cancers and high throughput flow cytometry assay to detect selective inhibitors | STC. UNM (US) | 2009-08-20 | — | — | US | claimed |
| WO-2009070331-A2 | COMPOUNDS AND METHODS FOR THE SELECTIVE INHIBITION OF ABCB1, ABCC1 AND ABCG2 TRANSPORTERS AND THE TREATMENT OF CANCERS, ESPECIALLY DRUG RESISTANT CANCERS AND HIGH THROUGHPUT FLOW CYTOMETRY ASSAY TO DETECT SELECTIVE INHIBITORS | STC.UNM (US) | 2009-06-04 | — | — | WO | claimed |
| EP-1773318-A1 | COMBINATION ANTICANCER THERAPY AND PHARMACEUTICAL COMPOSITIONS THEREFOR | OM Pharma (CH) | 2007-04-18 | — | — | EP | claimed |
| CN-1833636-A | Application of biphenyl cyclooctadiene lignin in treatment of tumour medicine | HU XUN (CN) | 2006-09-20 | — | — | CN | claimed |
| CN-1762450-A | Application of magnolia vine fruit in preparation of anti-tumor medicine or multi-medicine tolerant reversal agent | HU XUN (CN) | 2006-04-26 | — | — | CN | claimed |
| WO-2006011007-A1 | COMBINATION ANTICANCER THERAPY AND PHARMACEUTICAL COMPOSITIONS THEREFORE | OM PHARMA (CH) | 2006-02-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090214669-A1 | Combination anticancer therapy and pharmaceutical compositions therefore | LCK, BMX, YES1 | MAPT 3780/4885ALDH1A1 1358/4885LMNA 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.